Modeled Health Economic Impact of a Hypothetical Certolizumab Pegol Risk-Sharing Scheme for Patients with Moderate-to-Severe Rheumatoid Arthritis in Finland

Erkki Soini, Christian Asseburg, Maarit Taiha, Kari Puolakka, Oana Purcaru, Riitta Luosujärvi

Research output: Contribution to journalArticleScientificpeer-review

Original languageEnglish
JournalAdvances in Therapy
Volume34
Issue number10
Pages (from-to)2316-2332
Number of pages17
ISSN0741-238X
DOIs
Publication statusPublished - Oct 2017
MoE publication typeA1 Journal article-refereed

Fields of Science

  • Biological therapies
  • Certolizumab pegol
  • Disease-modifying antirheumatic drugs
  • Health economics
  • Health policies
  • Rheumatoid arthritis
  • Rheumatology
  • MODIFYING ANTIRHEUMATIC DRUGS
  • 5-YEAR FOLLOW-UP
  • QUALITY-OF-LIFE
  • COST-EFFECTIVENESS
  • EULAR RECOMMENDATIONS
  • PRODUCTIVITY COSTS
  • DISEASE-ACTIVITY
  • 2013 UPDATE
  • REGISTER
  • BURDEN
  • 3121 Internal medicine
  • 317 Pharmacy

Cite this

@article{5a5f7977dded465ba7e3040a640b5abb,
title = "Modeled Health Economic Impact of a Hypothetical Certolizumab Pegol Risk-Sharing Scheme for Patients with Moderate-to-Severe Rheumatoid Arthritis in Finland",
keywords = "Biological therapies, Certolizumab pegol, Disease-modifying antirheumatic drugs, Health economics, Health policies, Rheumatoid arthritis, Rheumatology, MODIFYING ANTIRHEUMATIC DRUGS, 5-YEAR FOLLOW-UP, QUALITY-OF-LIFE, COST-EFFECTIVENESS, EULAR RECOMMENDATIONS, PRODUCTIVITY COSTS, DISEASE-ACTIVITY, 2013 UPDATE, REGISTER, BURDEN, 3121 Internal medicine, 317 Pharmacy",
author = "Erkki Soini and Christian Asseburg and Maarit Taiha and Kari Puolakka and Oana Purcaru and Riitta Luosuj{\"a}rvi",
year = "2017",
month = "10",
doi = "10.1007/s12325-017-0614-8",
language = "English",
volume = "34",
pages = "2316--2332",
journal = "Advances in Therapy",
issn = "0741-238X",
publisher = "Springer",
number = "10",

}

Modeled Health Economic Impact of a Hypothetical Certolizumab Pegol Risk-Sharing Scheme for Patients with Moderate-to-Severe Rheumatoid Arthritis in Finland. / Soini, Erkki; Asseburg, Christian; Taiha, Maarit; Puolakka, Kari; Purcaru, Oana; Luosujärvi, Riitta.

In: Advances in Therapy, Vol. 34, No. 10, 10.2017, p. 2316-2332.

Research output: Contribution to journalArticleScientificpeer-review

TY - JOUR

T1 - Modeled Health Economic Impact of a Hypothetical Certolizumab Pegol Risk-Sharing Scheme for Patients with Moderate-to-Severe Rheumatoid Arthritis in Finland

AU - Soini, Erkki

AU - Asseburg, Christian

AU - Taiha, Maarit

AU - Puolakka, Kari

AU - Purcaru, Oana

AU - Luosujärvi, Riitta

PY - 2017/10

Y1 - 2017/10

KW - Biological therapies

KW - Certolizumab pegol

KW - Disease-modifying antirheumatic drugs

KW - Health economics

KW - Health policies

KW - Rheumatoid arthritis

KW - Rheumatology

KW - MODIFYING ANTIRHEUMATIC DRUGS

KW - 5-YEAR FOLLOW-UP

KW - QUALITY-OF-LIFE

KW - COST-EFFECTIVENESS

KW - EULAR RECOMMENDATIONS

KW - PRODUCTIVITY COSTS

KW - DISEASE-ACTIVITY

KW - 2013 UPDATE

KW - REGISTER

KW - BURDEN

KW - 3121 Internal medicine

KW - 317 Pharmacy

U2 - 10.1007/s12325-017-0614-8

DO - 10.1007/s12325-017-0614-8

M3 - Article

VL - 34

SP - 2316

EP - 2332

JO - Advances in Therapy

JF - Advances in Therapy

SN - 0741-238X

IS - 10

ER -